Invesco Ltd. Amylyx Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

$503 Billion
Q1 2025

A detailed history of Invesco Ltd. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 45,694 shares of AMLX stock, worth $289,243. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,694

Holding current value

$289,243

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$3.0 - $4.15 $137,082 - $189,630	45,694 New	45,694 $161,000
Q1 2024 May 14, 2024	BUY	$2.71 - $19.57 $1,230 - $8,884	454 Added 1.9%	24,349 $69,000
Q4 2023 Feb 12, 2024	SELL	$12.07 - $18.46 $71,695 - $109,652	-5,940 Reduced 19.91%	23,895 $351,000
Q3 2023 Nov 13, 2023	BUY	$18.08 - $23.45 $55,957 - $72,577	3,095 Added 11.57%	29,835 $546,000
Q2 2023 Aug 11, 2023	BUY	$20.98 - $31.42 $79,786 - $119,490	3,803 Added 16.58%	26,740 $576,000
Q1 2023 May 12, 2023	SELL	$27.71 - $40.93 $5.34 Million - $7.88 Million	-192,533 Reduced 89.35%	22,937 $672,000
Q4 2022 Feb 13, 2023	SELL	$29.75 - $39.26 $1.37 Million - $1.81 Million	-46,066 Reduced 17.61%	215,470 $7.96 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $4.49 Million - $8.09 Million	261,536 New	261,536 $7.36 Million

Others Institutions Holding AMLX

# of Institutions

150

Shares Held

72.6M

Call Options Held

148K

Put Options Held

98.7K

Perceptive Advisors LLC New York, NY

7.87M
Shares

$49.8 Million
1.17% of portfolio
Tcg Crossover Management, LLC Palo Alto, CA

5.94M
Shares

$37.6 Million
5.07% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

5.7M
Shares

$36.1 Million
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

4.12M
Shares

$26.1 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.08M
Shares

$19.5 Million
0.01% of portfolio

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $371M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account